On May 23, 2025, Mirxes Holding Company Limited (Mirxes) successfully listed on the Main Board of the Stock Exchange of Hong Kong (SEHK), raising net proceeds of approximately HK$880.5 million from its IPO (the “Listing”), with market capitalization of approximately HK$6,438.8 million. Wilson Sonsini Goodrich & Rosati acted as Hong Kong and U.S. counsel in the Listing to the underwriting syndicate led by joint sponsors China International Capital Corporation Hong Kong Securities Limited and CCB International Capital Limited.

Mirxes is a Singapore-headquartered micro ribonucleic acid (miRNA) technology company that is making diagnostic solutions for the screening of diseases accessible across key markets in Asia, including Singapore and China.

The Wilson Sonsini team was led by partners Yang Chu and Richard Wang and included Rujin Ruan, Giselle Ma, Kelly Cheng, and Kate Lam.